title: PARADIGM-HF--the experts' discussion.
authors.forename: Mariell
authors.initials: M
authors.lastname: Jessup
authors.forename: Keith A A
authors.initials: KA
authors.lastname: Fox
authors.forename: Michel
authors.initials: M
authors.lastname: Komajda
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
authors.forename: Milton
authors.initials: M
authors.lastname: Packer
mesh_terms: D000613:Aminobutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004338:Drug Combinations; D004656:Enalapril / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D013318:Stroke Volume; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D004656:Enalapril; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination